AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.05 Million USD | -35.3% |
| 2022 | -5.95 Million USD | 63.94% |
| 2021 | -16.51 Million USD | -145.41% |
| 2020 | -6.73 Million USD | 0.6% |
| 2019 | -6.77 Million USD | -0.25% |
| 2018 | -6.75 Million USD | -62.05% |
| 2017 | -4.16 Million USD | 28.26% |
| 2016 | -5.8 Million USD | 42.43% |
| 2015 | -10.09 Million USD | -1631.34% |
| 2014 | -582.94 Thousand USD | -553.39% |
| 2013 | -89.21 Thousand USD | -498.62% |
| 2012 | -14.9 Thousand USD | -433.43% |
| 2011 | -2794.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.26 Million USD | -676.54% |
| 2024 Q1 | -292.29 Thousand USD | 84.63% |
| 2023 FY | -8.05 Million USD | -35.3% |
| 2023 Q3 | 328.47 Thousand USD | 108.82% |
| 2023 Q4 | -1.9 Million USD | -679.12% |
| 2023 Q1 | -4.75 Million USD | -609.25% |
| 2023 Q2 | -3.72 Million USD | 21.73% |
| 2022 FY | -5.95 Million USD | 63.94% |
| 2022 Q2 | -1.38 Million USD | 54.44% |
| 2022 Q4 | 934.08 Thousand USD | 133.95% |
| 2022 Q1 | -3.04 Million USD | 62.23% |
| 2022 Q3 | -2.75 Million USD | -98.59% |
| 2021 Q3 | -3.29 Million USD | 13.99% |
| 2021 FY | -16.51 Million USD | -145.41% |
| 2021 Q1 | -864.53 Thousand USD | 63.93% |
| 2021 Q2 | -3.82 Million USD | -342.66% |
| 2021 Q4 | -8.04 Million USD | -144.53% |
| 2020 Q1 | -2.02 Million USD | -41.24% |
| 2020 Q4 | -2.39 Million USD | -25.77% |
| 2020 Q3 | -1.9 Million USD | -2300.29% |
| 2020 FY | -6.73 Million USD | 0.6% |
| 2020 Q2 | -79.38 Thousand USD | 96.09% |
| 2019 Q1 | -2.34 Million USD | -139.32% |
| 2019 FY | -6.77 Million USD | -0.25% |
| 2019 Q4 | -1.43 Million USD | -66.29% |
| 2019 Q3 | -863.61 Thousand USD | 52.16% |
| 2019 Q2 | -1.8 Million USD | 22.95% |
| 2018 Q2 | -1.67 Million USD | 39.26% |
| 2018 Q1 | -2.76 Million USD | -92.23% |
| 2018 FY | -6.75 Million USD | -62.05% |
| 2018 Q4 | -978.89 Thousand USD | 26.6% |
| 2018 Q3 | -1.33 Million USD | 20.55% |
| 2017 Q2 | -564.73 Thousand USD | -7.74% |
| 2017 Q1 | -524.16 Thousand USD | 55.71% |
| 2017 FY | -4.16 Million USD | 28.26% |
| 2017 Q4 | -1.43 Million USD | 12.43% |
| 2017 Q3 | -1.64 Million USD | -190.7% |
| 2016 Q2 | -1.88 Million USD | -97.94% |
| 2016 Q4 | -1.18 Million USD | 33.64% |
| 2016 Q1 | -954.1 Thousand USD | 84.91% |
| 2016 FY | -5.8 Million USD | 42.43% |
| 2016 Q3 | -1.78 Million USD | 5.56% |
| 2015 Q3 | -1.7 Million USD | -9.16% |
| 2015 Q2 | -1.56 Million USD | -207.86% |
| 2015 FY | -10.09 Million USD | -1631.34% |
| 2015 Q1 | -506.94 Thousand USD | -29.38% |
| 2015 Q4 | -6.32 Million USD | -271.05% |
| 2014 Q2 | -44.76 Thousand USD | -487.39% |
| 2014 FY | -582.94 Thousand USD | -553.39% |
| 2014 Q4 | -391.81 Thousand USD | -182.39% |
| 2014 Q3 | -138.74 Thousand USD | -209.95% |
| 2014 Q1 | -7621.00 USD | 82.26% |
| 2013 Q4 | -42.96 Thousand USD | -22713.16% |
| 2013 Q2 | -29.79 Thousand USD | -412.19% |
| 2013 Q1 | -5817.00 USD | 64.86% |
| 2013 FY | -89.21 Thousand USD | -498.62% |
| 2013 Q3 | 190.00 USD | 100.64% |
| 2012 Q1 | -510.00 USD | -141.87% |
| 2012 Q3 | 2400.00 USD | 1095.85% |
| 2012 Q2 | -241.00 USD | 52.75% |
| 2012 FY | -14.9 Thousand USD | -433.43% |
| 2012 Q4 | -16.55 Thousand USD | -789.71% |
| 2011 Q4 | 1218.00 USD | 130.36% |
| 2011 FY | -2794.00 USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | -4012.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -503.527% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -15.421% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 115.213% |
| Nascent Biotech, Inc. | -2.08 Million USD | -286.059% |
| Rebus Holdings, Inc. | -1.02 Million USD | -690.165% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 112.374% |
| Qrons Inc. | -789.34 Thousand USD | -921.057% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1174.445% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 87.125% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1839.853% |
| Skye Bioscience, Inc. | -37.64 Million USD | 78.59% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 89.248% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -22.56% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2847.924% |
| SQZ Biotechnologies Company | -79.46 Million USD | 89.857% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -178.651% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -342.711% |
| Mesoblast Limited | -87.95 Million USD | 90.837% |
| Marizyme, Inc. | -65.34 Million USD | 87.666% |
| Genus plc | 7.9 Million USD | 202.021% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 26.002% |
| Pharming Group N.V. | -10.54 Million USD | 23.59% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -271.446% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -117.228% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 8.868% |
| ContraFect Corporation | -65.15 Million USD | 87.63% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -64.952% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -366.564% |
| IMV Inc. | -36.48 Million USD | 77.91% |
| MultiCell Technologies, Inc. | -380.07 USD | -2120478.315% |
| ONE Bio Corp. | 8.67 Million USD | 192.89% |
| Accustem Sciences Inc. | -3.74 Million USD | -115.13% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 84.408% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -536.056% |
| Q BioMed Inc. | -2.05 Million USD | -292.754% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -115.904% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -238.518% |
| Biomind Labs Inc. | -1.21 Million USD | -563.72% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 86.505% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -159.842% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1.981% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -313.476% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -53717.321% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 49.219% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -38.548% |
| GB Sciences, Inc. | -1.36 Million USD | -491.894% |
| Alpha Cognition Inc. | -13.77 Million USD | 41.48% |
| HST Global, Inc. | -146.21 Thousand USD | -5412.401% |
| CSL Limited | 2.64 Billion USD | 100.305% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -359.301% |
| Halberd Corporation | -79.67 Thousand USD | -10015.571% |
| Enzolytics Inc. | -2.17 Million USD | -270.248% |
| Agentix Corp. | -1.37 Million USD | -486.495% |
| Resverlogix Corp. | -3.61 Million USD | -123.26% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -154.134% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.268% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 8324.165% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 216.392% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -102.862% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -166.336% |
| AVAX Technologies, Inc. | -6.41 Million USD | -25.665% |
| Zenith Capital Corp. | -10.59 Million USD | 23.937% |
| Genscript Biotech Corporation | -95.47 Million USD | 91.559% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -34577.231% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -94.4% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -13234.879% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -301.956% |
| Kadimastem Ltd | -3.3 Million USD | -143.686% |
| Helix BioMedix, Inc. | -1.05 Million USD | -663.186% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -111.042% |
| BioStem Technologies, Inc. | -8.48 Million USD | 4.99% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1726.064% |
| LadRx Corporation | 400.44 Thousand USD | 2112.691% |
| Cell Source, Inc. | -5.32 Million USD | -51.463% |
| Regen BioPharma, Inc. | 1.02 Million USD | 887.457% |
| Regen BioPharma, Inc. | 1.02 Million USD | 887.457% |
| NovAccess Global Inc. | -4.76 Million USD | -68.995% |
| Affymax, Inc. | -14.42 Million USD | 44.123% |
| Itoco Inc. | -1.86 Million USD | -331.231% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -81.421% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -382.905% |
| Mobile Lads Corp. | -2.26 Million USD | -256.104% |
| CytoDyn Inc. | -49.84 Million USD | 83.829% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -10097.869% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3432.98% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -756.021% |
| SYBLEU INC | -180.3 Thousand USD | -4370.052% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -399.752% |
| International Stem Cell Corporation | -131 Thousand USD | -6052.429% |
| Bioxytran, Inc. | -4.28 Million USD | -88.31% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -14750.534% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -218.533% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 83.234% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -281.253% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -932.119% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -154.409% |
| Neutra Corp. | -233.46 Thousand USD | -3352.201% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 60.28% |
| PureTech Health plc | -65.69 Million USD | 87.732% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 62.102% |
| IXICO plc | -1.17 Million USD | -584.184% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 18.81% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 85.892% |
| CSL Limited | 2.64 Billion USD | 100.305% |
| Cellectis S.A. | -103.17 Million USD | 92.188% |